Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus TKI as preoperative therapy for advanced renal cell carcinoma
ChiCTR2000038249Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab, pazopanib, axitinib and sunitinib in renal cell carcinoma (RCC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: overall survival and objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
toripalimabpazopanibaxitinibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2000038249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038249.